Drug Profile


Alternative Names: BCX-4161

Latest Information Update: 13 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioCryst Pharmaceuticals
  • Class Anti-inflammatories; Carboxylic acids; Cyclopropanes; Pyridines; Small molecules
  • Mechanism of Action Bradykinin inhibitors; Kallikrein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hereditary angioedema
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hereditary angioedema

Most Recent Events

  • 13 Oct 2016 Discontinued - Phase-I for Hereditary angioedema (Prevention) in USA (PO) due to insignificant phase I data (Biocryst Pharmaceuticals pipeline and Biocryst Pharmaceuticals 10-Q, August 2016)
  • 26 Feb 2016 Phase I clinical trials in Hereditary angioedema (Prevention) in USA (PO, Hard-gelatin capsule) before February 2016
  • 24 Feb 2016 Discontinued - Phase-II/III for Hereditary angioedema (Prevention) in USA, Belgium, Canada, Italy, United Kingdom (PO, Soft-gelatin capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top